Evidence map›Paper›PMID 35189962›Full record

ReviewStem cell research & therapy2022

Enhancement strategies for mesenchymal stem cells and related therapies.

Senthilkumar Alagesan, Jack Brady, Declan Byrnes, Juan Fandiño, Claire Masterson, Sean McCarthy, John Laffey, Daniel O'Toole

Open access · goldAbstract readReview
In one paragraph

Review in Stem cell research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Senthilkumar Alagesan *Discipline of Anaesthesia, National University of Ireland, Galway, Ireland.
Jack Brady *Discipline of Anaesthesia, National University of Ireland, Galway, Ireland.
Declan Byrnes *Discipline of Anaesthesia, National University of Ireland, Galway, Ireland.
Juan Fandiño *Discipline of Anaesthesia, National University of Ireland, Galway, Ireland.
Claire Masterson *Discipline of Anaesthesia, National University of Ireland, Galway, Ireland.
Sean McCarthy *Discipline of Anaesthesia, National University of Ireland, Galway, Ireland.
John Laffey *Discipline of Anaesthesia, National University of Ireland, Galway, Ireland.
Daniel O'TooleDiscipline of Anaesthesia, National University of Ireland, Galway, Ireland. daniel.otoole@nuigalway.ie.ORCID 0000-0001-5422-8711
Ollscoil na Gaillimhe – University of Galway · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell therapy, particularly mesenchymal stem/stromal (MSC) therapy, has been investigated for a wide variety of disease indications, particularly those with inflammatory pathologies. However, recently it has become evident that the MSC is far from a panacea. In this review we will look at current and future strategies that might overcome limitations in efficacy. Many of these take their inspiration from stem cell niche and the mechanism of MSC action in response to the injury microenvironment, or from previous gene therapy work which can now benefit from the added longevity and targeting ability of a live cell vector. We will also explore the nascent field of extracellular vesicle therapy and how we are already seeing enhancement protocols for this exciting new drug. These enhanced MSCs will lead the way in more difficult to treat diseases and restore potency where donors or manufacturing practicalities lead to diminished MSC effect.

Indexed as

Extracellular VesiclesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationCell- and Tissue-Based TherapySignal TransductionStem Cell NicheCell therapyExtracellular vesiclesPrimingStem cells

Identifiers

PMID35189962
PMCPMC8860135
OpenAlexW4212994220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.